TABLE 2.
Summary of meta-analysis.
| Outcomes | No. of studies | No. of participants | Effect size (95% CI) | I2 |
|---|---|---|---|---|
| 28-day mortality | 9 | 708 | RR, 0.66 (0.56, 0.77) | 0 |
| HR | 11 | 749 | SMD, −1.70 (−2.24, −1.17) | 89.6% |
| MAP | 9 | 611 | SMD, 0.13 (−0.03, 0.29) | 0 |
| cTnI | 6 | 329 | SMD, −1.61 (−2.06, −1.16) | 68.6% |
| Lac | 9 | 507 | SMD, −0.16 (−0.80, 0.49) | 91.7% |
| CI | 7 | 399 | SMD, 0.13 (−0.82, 1.08) | 94.9% |
| SVI | 6 | 339 | SMD, 0.67 (−0.04, 1.39) | 89.8% |
HR, heart rate; MAP, mean arterial pressure; Lac, lactate; CI, cardiac index; SVI, stroke volume index; RR, relative risks; WMD, weighted mean difference.